OPT Insider Trading

Insider Ownership Percentage: 5.69%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$1,656,752.35

Opthea Insider Trading History Chart

This chart shows the insider buying and selling history at Opthea by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Opthea Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for OPT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Opthea Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2024Megan BaldwinInsiderSell3,012,277A$0.55A$1,656,752.35
12/21/2023Megan BaldwinInsiderIssued3,000,000A$0.47A$1,410,000.00
11/28/2022Michael SistenichInsiderBuy177,951A$0.48A$85,416.48
11/11/2021Megan BaldwinInsiderIssued1,600,000A$1.21A$1,936,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Opthea (ASX:OPT)

31.73% of Opthea stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Opthea logo
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Read More on Opthea

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


504,572 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Opthea?

Opthea's top insider investors include:
  1. Megan Baldwin (Insider)
  2. Michael Sistenich (Insider)
Learn More about top insider investors at Opthea.